Page 1

CADRENAL THERAPEUTICS Strategic Partnering Opportunity Advancing High - value Cardiac Acute Critical Care & Orphan Disease Drug Assets September 2026 Nasdaq : CVKD 3 Orphan Drug Designations ( FDA ) > $ 3B Total Peak Annual Revenue Potential